drugset
Drugs / PGDM1400LS
last change Mar 2026 re-read 2 minutes ago

PGDM1400LS

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Department of Health and Human Services · National Institutes of Health (NIH) · Henry M. Jackson Foundation for the Advancement of Military Medicine · US Military HIV Research Program · Dale and Betty Bumpers Vaccine Research Center (VRC)
+2 more · HIV Vaccine Trials Network · Janssen Vaccines & Prevention B.V.

Trials 7 · a red edge is where a trial was stopped

today NCT07390955 · Ph 1 NCT06484335 · Ph 1 NCT06812494 · Ph 2 NCT06508749 · Ph 1/2 NCT05959707 · Ph 1 NCT05769569 · Ph 1 NCT05184452 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07390955 Mar 2026 → Aug 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1 NCT06484335 Mar 2025 → Aug 2027 expected HIV infectious disease Henry M. Jackson Foundation for the Advancement of Military Medicine Recruiting No outcome recorded
Phase 1 NCT05959707 Aug 2024 → Jan 2025 HIV infectious disease HIV Vaccine Trials Network Suspended No outcome recorded
Phase 1 NCT05769569 Sep 2023 → Jul 2025 HIV infectious disease Henry M. Jackson Foundation for the Advancement of Military Medicine Withdrawn No outcome recorded
Phase 1 NCT05184452 Nov 2021 → Jul 2023 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06508749 Nov 2024 → Sep 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06812494 Mar 2025 → Jan 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as PGDM1400-LS “The study enrolled participants at four sites in the USA, across five groups, each receiving one dose of PGDM1400-LS intravenously (group 1: 5 mg/kg; group 2: 20 mg/kg; and...” PMID 40441807 ↗ Jun 2025
7

NCT05769569 ↗

NCT07390955 ↗

NCT05184452 ↗

NCT06812494 ↗

NCT06508749 ↗

NCT05959707 ↗

NCT06484335 ↗
Modality Monoclonal antibody “recombinant human IgG1 bNAb” NCT05769569 ↗
Route Intravenous “Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.” NCT05769569 ↗